These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38651316)

  • 21. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.
    Loblaw DA; Virgo KS; Nam R; Somerfield MR; Ben-Josef E; Mendelson DS; Middleton R; Sharp SA; Smith TJ; Talcott J; Taplin M; Vogelzang NJ; Wade JL; Bennett CL; Scher HI;
    J Clin Oncol; 2007 Apr; 25(12):1596-605. PubMed ID: 17404365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-line use of novel hormonal agents in prostate cancer: a critical appraisal.
    Raghavan D
    Clin Adv Hematol Oncol; 2018 Apr; 16(4):289-295. PubMed ID: 29742084
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Current treatment of locally advanced and metastatic prostate cancer].
    Ponholzer A; Steinbacher F; Madersbacher S; Schramek P
    Wien Med Wochenschr; 2011 Aug; 161(15-16):377-81. PubMed ID: 21953428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ; George DJ
    Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):108-16. PubMed ID: 20066005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Agents that target androgen synthesis in castration-resistant prostate cancer.
    Ferraldeschi R; de Bono J
    Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer.
    Borno HT; Lichtensztajn DY; Gomez SL; Palmer NR; Ryan CJ
    Cancer; 2019 Feb; 125(3):453-462. PubMed ID: 30444526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SEOM clinical guidelines for the treatment of advanced prostate cancer (2020).
    González Del Alba A; Méndez-Vidal MJ; Vazquez S; Castro E; Climent MA; Gallardo E; Gonzalez-Billalabeitia E; Lorente D; Maroto JP; Arranz JA
    Clin Transl Oncol; 2021 May; 23(5):969-979. PubMed ID: 33625671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Maximal androgen blockade in the treatment of patients with disseminated cancer of the prostate].
    Matveev BP; Bukharkin BV
    Vopr Onkol; 1998; 44(5):537-40. PubMed ID: 9884710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contemporary role of androgen deprivation therapy for prostate cancer.
    Pagliarulo V; Bracarda S; Eisenberger MA; Mottet N; Schröder FH; Sternberg CN; Studer UE
    Eur Urol; 2012 Jan; 61(1):11-25. PubMed ID: 21871711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with
    Turner PG; Jain S; Cole A; Grey A; Mitchell D; Prise KM; Hounsell AR; McGarry CK; Biggart S; O'Sullivan JM
    Clin Cancer Res; 2021 Aug; 27(16):4549-4556. PubMed ID: 34187853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel agents for metastatic hormone-sensitive prostate cancer - a practice guide for urologists.
    Thangasamy IA; Kwan EM; Teh J; Sathianathen N; Alghazo O; Siva S; Azad A; Murphy DG
    BJU Int; 2020 Mar; 125(3):342-345. PubMed ID: 31660679
    [No Abstract]   [Full Text] [Related]  

  • 32. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
    MacVicar GR; Hussain MH
    Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan.
    Leith A; Ribbands A; Kim J; Clayton E; Gillespie-Akar L; Yang L; Ghate SR
    BMC Urol; 2022 Mar; 22(1):33. PubMed ID: 35277153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol.
    Chang A; Yeap B; Davis T; Blum R; Hahn R; Khanna O; Fisher H; Rosenthal J; Witte R; Schinella R; Trump D
    J Clin Oncol; 1996 Aug; 14(8):2250-7. PubMed ID: 8708714
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma.
    Chodak G; Sharifi R; Kasimis B; Block NL; Macramalla E; Kennealey GT
    Urology; 1995 Dec; 46(6):849-55. PubMed ID: 7502428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hormone therapy in prostate cancer; a pharmacotherapeutic challenge].
    Westdorp H; Benoist GE; Schers HJ; van Erp PH; Gerritsen WR; Mulders PF; Kramers C
    Ned Tijdschr Geneeskd; 2015; 159():A9250. PubMed ID: 26246066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Androgen-deprivation therapy in prostate cancer: clinical evidence and future perspectives].
    Pinto F; Calarco A; Totaro A; Sacco E; Volpe A; Racioppi M; D'Addessi A; Bassi PF
    Urologia; 2010; 77(2):71-83. PubMed ID: 20890863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The androgen receptor, androgen synthesis, and new designer antiandrogens for metastatic castration-resistant prostate cancer: teaching old dogs new tricks.
    Lieberman R
    Am J Ther; 2013; 20(2):128-31. PubMed ID: 23466618
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.